// App-Quantinova.ai

: Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1

Researchers

Presenter

  • Joachim Ficker

Principal Investigators

  • Kenneth R. Chapman

  • Alice Turner

  • Robert A. Sandhaus

  • Marion Wencker

  • Oliver Vit

  • Michael Fries

  • N.G. McElvaney

Medical Centers

  • Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University / General Hospital Nuremberg, Nuremberg, Germany,

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • Institute of Inflammation and Ageing, Centre for Translational Inflammation Research, Queen Elizabeth Hospital, Birmingham, United Kingdom,

  • National Jewish Health, Denver, CO, United States

  • Medical Affairs, CSL Behring, Marburg, Germany,

  • Clinical Research and Development, CSL Behring, Bern, Switzerland,

  • Clinical Strategy and Development, CSL Behring, King of Prussia, PA, United States,

  • Department of Respiratory Medicine, Beaumont Hospital, Royal College of Surgeons, Dublin, Ireland

Locations

  • Germany

  • Canada

  • United Kingdom

  • United States

  • Switzerland

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Alpha-1 antitrypsin

Drug/Treatment

  • Alpha 1-Antitrypsin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved